Déterminants sociaux de la santé : Questions médicales fréquentes
Nom anglais: Social Determinants of Health
Descriptor UI:D064890
Tree Number:N01.400.675
Termes MeSH sélectionnés :
Prothrombin Time
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Déterminants sociaux de la santé : Questions médicales les plus fréquentes",
"headline": "Déterminants sociaux de la santé : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Déterminants sociaux de la santé : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-01-20",
"dateModified": "2025-04-14",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Déterminants sociaux de la santé"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Santé",
"url": "https://questionsmedicales.fr/mesh/D006262",
"about": {
"@type": "MedicalCondition",
"name": "Santé",
"code": {
"@type": "MedicalCode",
"code": "D006262",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "N01.400"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Déterminants sociaux de la santé",
"alternateName": "Social Determinants of Health",
"code": {
"@type": "MedicalCode",
"code": "D064890",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Mofya S Diallo",
"url": "https://questionsmedicales.fr/author/Mofya%20S%20Diallo",
"affiliation": {
"@type": "Organization",
"name": "Department of Anesthesiology Critical Care Medicine, Children's Hospital Los Angeles, Keck School of Medicine at the University of Southern California, 4650 Sunset Boulevard, MS#3, Los Angeles, CA 90027, USA. Electronic address: modiallo@chla.usc.edu."
}
},
{
"@type": "Person",
"name": "Sacharitha Bowers",
"url": "https://questionsmedicales.fr/author/Sacharitha%20Bowers",
"affiliation": {
"@type": "Organization",
"name": "Division of Dermatology, Department of Internal Medicine, Loyola University Medical Center, Stritch School of Medicine, 1S260 Summit Ave, Oakbrook Terrace, IL 60181, USA. Electronic address: sachbow@gmail.com."
}
},
{
"@type": "Person",
"name": "Aileen Y Chang",
"url": "https://questionsmedicales.fr/author/Aileen%20Y%20Chang",
"affiliation": {
"@type": "Organization",
"name": "Department of Dermatology, University of California San Francisco, Zuckerberg San Francisco General Hospital, 995 Potrero Avenue, Building 90, Ward 92, San Francisco, CA 94110, USA."
}
},
{
"@type": "Person",
"name": "Christina Pardo",
"url": "https://questionsmedicales.fr/author/Christina%20Pardo",
"affiliation": {
"@type": "Organization",
"name": "Department of Obstetrics and Gynecology, Weill Cornell Medicine, New York, NY, USA. Electronic address: chp4022@med.cornell.edu."
}
},
{
"@type": "Person",
"name": "Julianne Holt-Lunstad",
"url": "https://questionsmedicales.fr/author/Julianne%20Holt-Lunstad",
"affiliation": {
"@type": "Organization",
"name": "Department of Psychology, Brigham Young University, Provo, Utah, USA; email: julianne_holt-lunstad@byu.edu."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Frequency of prothrombin time-international normalized ratio monitoring and the long-term prognosis in patients with mechanical valve replacement.",
"datePublished": "2023-06-24",
"url": "https://questionsmedicales.fr/article/37355558",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s12872-023-03293-w"
}
},
{
"@type": "ScholarlyArticle",
"name": "Association between prothrombin time-international normalized ratio and prognosis of post-cardiac arrest patients: A retrospective cohort study.",
"datePublished": "2023-01-20",
"url": "https://questionsmedicales.fr/article/36741950",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3389/fpubh.2023.1112623"
}
},
{
"@type": "ScholarlyArticle",
"name": "Alteration of prothrombin time in Plasmodium falciparum and Plasmodium vivax infections with different levels of severity: a systematic review and meta-analysis.",
"datePublished": "2024-05-02",
"url": "https://questionsmedicales.fr/article/38698102",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1038/s41598-024-60170-y"
}
},
{
"@type": "ScholarlyArticle",
"name": "Development of a paper-based lateral flow prothrombin assay.",
"datePublished": "2022-10-06",
"url": "https://questionsmedicales.fr/article/36048161",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1039/d2ay00965j"
}
},
{
"@type": "ScholarlyArticle",
"name": "Evaluation of newly-developed modified diluted prothrombin time reagent in non-valvular atrial fibrillation patients with direct oral anticoagulants: A comparative study with conventional reagents.",
"datePublished": "2022-09-16",
"url": "https://questionsmedicales.fr/article/36114152",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/ijlh.13971"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Caractéristiques de la population",
"item": "https://questionsmedicales.fr/mesh/D011154"
},
{
"@type": "ListItem",
"position": 3,
"name": "Santé",
"item": "https://questionsmedicales.fr/mesh/D006262"
},
{
"@type": "ListItem",
"position": 4,
"name": "Déterminants sociaux de la santé",
"item": "https://questionsmedicales.fr/mesh/D064890"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Déterminants sociaux de la santé - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Déterminants sociaux de la santé",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-16",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Déterminants sociaux de la santé",
"description": "Comment évaluer l'impact des déterminants sociaux sur la santé ?\nQuels outils mesurent les déterminants sociaux de la santé ?\nQuels indicateurs sont utilisés pour le diagnostic social ?\nComment les inégalités sociales affectent-elles la santé ?\nQuel rôle joue l'environnement dans le diagnostic social ?",
"url": "https://questionsmedicales.fr/mesh/D064890?mesh_terms=Prothrombin+Time&page=2#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Déterminants sociaux de la santé",
"description": "Quels symptômes peuvent indiquer des déterminants sociaux défavorables ?\nComment la pauvreté affecte-t-elle la santé mentale ?\nQuels symptômes physiques sont liés à des conditions sociales ?\nLes inégalités sociales provoquent-elles des symptômes spécifiques ?\nComment l'accès limité aux soins se manifeste-t-il ?",
"url": "https://questionsmedicales.fr/mesh/D064890?mesh_terms=Prothrombin+Time&page=2#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Déterminants sociaux de la santé",
"description": "Quelles stratégies de prévention ciblent les déterminants sociaux ?\nComment sensibiliser aux déterminants sociaux de la santé ?\nQuel rôle des communautés dans la prévention ?\nComment les politiques publiques influencent-elles la prévention ?\nQuels programmes de prévention sont efficaces ?",
"url": "https://questionsmedicales.fr/mesh/D064890?mesh_terms=Prothrombin+Time&page=2#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Déterminants sociaux de la santé",
"description": "Comment adapter les traitements aux déterminants sociaux ?\nQuels traitements sont efficaces pour les populations défavorisées ?\nComment les services de santé peuvent-ils réduire les inégalités ?\nQuel rôle joue l'éducation dans le traitement des maladies ?\nComment les politiques de santé influencent-elles les traitements ?",
"url": "https://questionsmedicales.fr/mesh/D064890?mesh_terms=Prothrombin+Time&page=2#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Déterminants sociaux de la santé",
"description": "Quelles complications sont liées aux inégalités sociales ?\nComment les déterminants sociaux aggravent-ils les maladies ?\nQuels sont les effets à long terme des déterminants sociaux ?\nComment prévenir les complications liées aux déterminants sociaux ?\nLes complications de santé sont-elles évitables ?",
"url": "https://questionsmedicales.fr/mesh/D064890?mesh_terms=Prothrombin+Time&page=2#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Déterminants sociaux de la santé",
"description": "Quels sont les principaux facteurs de risque sociaux ?\nComment l'éducation influence-t-elle les facteurs de risque ?\nQuel impact a l'emploi sur la santé ?\nComment l'environnement social affecte-t-il la santé ?\nQuels facteurs de risque sont liés à l'accès aux soins ?",
"url": "https://questionsmedicales.fr/mesh/D064890?mesh_terms=Prothrombin+Time&page=2#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment évaluer l'impact des déterminants sociaux sur la santé ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'impact peut être évalué par des études épidémiologiques et des enquêtes sociales."
}
},
{
"@type": "Question",
"name": "Quels outils mesurent les déterminants sociaux de la santé ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des questionnaires standardisés et des indices de conditions de vie sont utilisés."
}
},
{
"@type": "Question",
"name": "Quels indicateurs sont utilisés pour le diagnostic social ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les indicateurs incluent le revenu, l'éducation, et l'accès aux soins de santé."
}
},
{
"@type": "Question",
"name": "Comment les inégalités sociales affectent-elles la santé ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les inégalités sociales peuvent entraîner des disparités dans l'accès aux soins et la santé."
}
},
{
"@type": "Question",
"name": "Quel rôle joue l'environnement dans le diagnostic social ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'environnement physique et social influence la santé par l'accès aux ressources."
}
},
{
"@type": "Question",
"name": "Quels symptômes peuvent indiquer des déterminants sociaux défavorables ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes de stress, dépression ou maladies chroniques peuvent apparaître."
}
},
{
"@type": "Question",
"name": "Comment la pauvreté affecte-t-elle la santé mentale ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "La pauvreté peut entraîner une augmentation de l'anxiété et de la dépression."
}
},
{
"@type": "Question",
"name": "Quels symptômes physiques sont liés à des conditions sociales ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des maladies comme l'hypertension et le diabète peuvent être exacerbées par des conditions sociales."
}
},
{
"@type": "Question",
"name": "Les inégalités sociales provoquent-elles des symptômes spécifiques ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles peuvent entraîner des symptômes de maladies évitables et chroniques."
}
},
{
"@type": "Question",
"name": "Comment l'accès limité aux soins se manifeste-t-il ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il se manifeste par des symptômes non traités et des complications de santé."
}
},
{
"@type": "Question",
"name": "Quelles stratégies de prévention ciblent les déterminants sociaux ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des programmes d'éducation, d'accès aux soins et de soutien communautaire sont essentiels."
}
},
{
"@type": "Question",
"name": "Comment sensibiliser aux déterminants sociaux de la santé ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Par des campagnes d'information et des formations pour les professionnels de santé."
}
},
{
"@type": "Question",
"name": "Quel rôle des communautés dans la prévention ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les communautés peuvent mobiliser des ressources et créer des réseaux de soutien."
}
},
{
"@type": "Question",
"name": "Comment les politiques publiques influencent-elles la prévention ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles peuvent promouvoir l'équité en santé et améliorer l'accès aux services."
}
},
{
"@type": "Question",
"name": "Quels programmes de prévention sont efficaces ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les programmes intégrés qui abordent plusieurs déterminants sociaux sont les plus efficaces."
}
},
{
"@type": "Question",
"name": "Comment adapter les traitements aux déterminants sociaux ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements doivent tenir compte des ressources et des conditions de vie des patients."
}
},
{
"@type": "Question",
"name": "Quels traitements sont efficaces pour les populations défavorisées ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les programmes de santé communautaire et les interventions ciblées sont efficaces."
}
},
{
"@type": "Question",
"name": "Comment les services de santé peuvent-ils réduire les inégalités ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "En offrant des soins accessibles et adaptés aux besoins des populations vulnérables."
}
},
{
"@type": "Question",
"name": "Quel rôle joue l'éducation dans le traitement des maladies ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'éducation améliore l'adhésion aux traitements et la gestion des maladies."
}
},
{
"@type": "Question",
"name": "Comment les politiques de santé influencent-elles les traitements ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles déterminent l'accès aux soins et les ressources disponibles pour les traitements."
}
},
{
"@type": "Question",
"name": "Quelles complications sont liées aux inégalités sociales ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent des maladies chroniques non traitées et des décès prématurés."
}
},
{
"@type": "Question",
"name": "Comment les déterminants sociaux aggravent-ils les maladies ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils peuvent entraîner un accès limité aux soins et une mauvaise gestion des maladies."
}
},
{
"@type": "Question",
"name": "Quels sont les effets à long terme des déterminants sociaux ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils peuvent mener à des problèmes de santé persistants et à une qualité de vie réduite."
}
},
{
"@type": "Question",
"name": "Comment prévenir les complications liées aux déterminants sociaux ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "En améliorant l'accès aux soins et en renforçant les réseaux de soutien communautaire."
}
},
{
"@type": "Question",
"name": "Les complications de santé sont-elles évitables ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, de nombreuses complications peuvent être évitées par des interventions précoces."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque sociaux ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent la pauvreté, le manque d'éducation et l'isolement social."
}
},
{
"@type": "Question",
"name": "Comment l'éducation influence-t-elle les facteurs de risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une éducation supérieure est associée à une meilleure santé et à des comportements préventifs."
}
},
{
"@type": "Question",
"name": "Quel impact a l'emploi sur la santé ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un emploi stable améliore la santé mentale et physique, réduisant les risques."
}
},
{
"@type": "Question",
"name": "Comment l'environnement social affecte-t-il la santé ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un environnement social positif favorise le bien-être et réduit les risques de maladies."
}
},
{
"@type": "Question",
"name": "Quels facteurs de risque sont liés à l'accès aux soins ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le manque d'accès aux soins médicaux et préventifs augmente les risques de maladies."
}
}
]
}
]
}
The study aimed to assess the correlation between the monitoring frequency of PT-INR and the long-term prognosis in patients with mechanical heart valve (MHV) replacement after discharge....
This single-center, observational study enrolled patients who underwent MHV replacement and discharged from June 2015 to May 2018. Patients or their corresponding family members were followed with a t...
A total of 188 patients were included in the final analysis. The median follow-up duration was 3.6 years (Interquartile range: 2.6 to 4.4 years). 104 (55.3%) patients and 84 (44.7%) patients were clas...
The management of warfarin treatment in patients after MHV replacement remains challenging. Patients with less frequent monitoring of PT-INR might have worse clinical prognosis than those with frequen...
Cardiac arrest (CA) can activate blood coagulation. This study aimed to explore the potential prognostic value of prothrombin time-international normalized ratio (INR) in post-CA patients....
The clinical data of eligible subjects diagnosed with CA was extracted from the MIMIC-IV database as the training cohort. Restricted cubic spline (RCS), Kaplan-Meier (K-M) survival curve, and Cox regr...
A total of 1,324 subjects were included in the training cohort. A linear correlation existed between INR and the risk of all-cause death of post-CA patients, as shown in RCS analysis, with a hazard ra...
We systematically and comprehensively demonstrated that elevated INR was associated with increased short- and long-term all-cause mortality of post-CA patients. Therefore, elevated INR may be a promis...
Malaria infection leads to hematological abnormalities, including deranged prothrombin time (PT). Given the inconsistent findings regarding PT in malaria across different severities and between Plasmo...
Disorders of haemostasis result in both excessive bleeding and clotting and are a major global cause of morbidity and mortality, particularly in the developing world. A small number of simple tests ca...
A single assay to assess the effect of the direct FXa inhibitor is needed clinically because prothrombin (PT) assay is not yet sensitive enough for accurate evaluation. We developed modified diluted p...
The correlation and slopes of mdPT against the drug concentrations by anti-Xa assay were compared to those of the four commercial reagents of PT or dPT in 275, 257, and 243 clinical samples collected ...
The correlation coefficient (95% confidence interval) of mdPT against apixaban, edoxaban, and rivaroxaban was 0.818 (0.775-0.854), 0.914 (0.892-0.932), and 0.814 (0.766-0.852), respectively. The slope...
Compared with other PT and dPT reagents, mdPT reagent showed sharper slope to all direct FXa inhibitors, and higher correlation to apixaban and comparable correlation to edoxaban and rivaroxaban. This...
The study of ABCB1 and CYP3A4/3A5 gene polymorphism genes is promising in terms of their influence on prothrombin time variability, the residual equilibrium concentration of direct oral anticoagulants...
In total 86 patients (42 men and 44 female), aged 67.24 ± 1.01 years with atrial fibrillation were enrolled in the study. HPLC mass spectrometry analysis was used to determine rivaroxaban residual equ...
The residual equilibrium concentration of rivaroxaban in patients with ABCB1 rs4148738 CT genotype is significantly higher than in patients with ABCB1 rs4148738 CC (P = 0.039). The analysis of the com...
Patients with ABCB1 rs4148738 CT genotype have a statistically significantly higher residual equilibrium concentration of rivaroxaban in blood than patients with ABCB1 rs4148738 CC genotype, which sho...
The association between prothrombin time-international normalized ratio (PT-INR) and long-term prognosis among patients with coronary artery disease (CAD) without atrial fibrillation or anticoagulant ...
We obtained data from 44,662 patients who were diagnosed with CAD and had follow-up information from January 2008 to December 2018. The patients were divided into 4 groups (Quartile 1: PT-INR ≤ 0.96; ...
During a median follow-up of 5.25 years, 5613 (12.57%) patients died. We observed a non-linear shaped association between PT-INR levels and long-term all-cause mortality. Patients in high PT-INR level...
Our study demonstrates high levels of PT-INR were associated with an increased risk of all-cause mortality....
Post-hepatectomy liver failure (PHLF) is a serious complication associated with major hepatectomies. An accurate prediction of PHLF is necessary to determine the feasibility of major hepatectomy. This...
Medical records of 65 patients who underwent major hepatectomy and preoperative CT were retrospectively reviewed. We evaluated future remnant liver volume evaluation models and remnant liver hemodynam...
The PHLF group included 21 patients (32.3%). The AEF was not significantly different between the two groups. In the future remnant liver volume evaluation models, future remnant liver proportion (fRLP...
The APART score may help predict PHLF in patients indicated for major hepatectomies....
The management of factor Xa (FXa) inhibitor-associated bleeding remains a clinical challenge. Massive bleeding is often associated with complex coagulopathy and, thus, the sole reversal of FXa inhibit...
Lupus anticoagulant (LA) is composed of heterogeneous autoantibodies, which have a close association with thrombotic events. Due to its heterogeneity, two methods for increasing sensitivity are recomm...